ATE463491T1 - Indolylmaleimid derivate - Google Patents

Indolylmaleimid derivate

Info

Publication number: ATE463491T1
Authority: AT; Austria
Prior art keywords: indolylmaleimide derivatives; indolylmaleimide; derivatives; gsk; pkc
Prior art date: 2003-02-13

Application number

AT04710393T

Other languages

English (en)

Inventor

Matt Peter Von

Juergen Wagner

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-13

Filing date

2004-02-12

Publication date

2010-04-15

2004-02-12 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2010-04-15 Application granted granted Critical

2010-04-15 Publication of ATE463491T1 publication Critical patent/ATE463491T1/de

Links

WIQRSJOCVVPMPS-UHFFFAOYSA-N 3-(1h-indol-2-yl)pyrrole-2,5-dione Chemical class O=C1NC(=O)C(C=2NC3=CC=CC=C3C=2)=C1 WIQRSJOCVVPMPS-UHFFFAOYSA-N 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 abstract 1
108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Virology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)

AT04710393T 2003-02-13 2004-02-12 Indolylmaleimid derivate ATE463491T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0303319.8A GB0303319D0 (en)	2003-02-13	2003-02-13	Organic compounds
PCT/EP2004/001323 WO2004072062A2 (en)	2003-02-13	2004-02-12	Indolylmaleimide derivatives

Publications (1)

Publication Number	Publication Date
ATE463491T1 true ATE463491T1 (de)	2010-04-15

Family

ID=9952961

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT09004073T ATE551335T1 (de)	2003-02-13	2004-02-12	Indolylmaleimid-derivate
AT04710393T ATE463491T1 (de)	2003-02-13	2004-02-12	Indolylmaleimid derivate

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT09004073T ATE551335T1 (de)	2003-02-13	2004-02-12	Indolylmaleimid-derivate

Country Status (12)

Country	Link
US (1)	US7820672B2 (de)
EP (2)	EP1597250B8 (de)
JP (2)	JP2006515004A (de)
CN (1)	CN100439359C (de)
AT (2)	ATE551335T1 (de)
BR (1)	BRPI0407512A (de)
CA (1)	CA2513613A1 (de)
DE (1)	DE602004026415D1 (de)
ES (2)	ES2385071T3 (de)
GB (1)	GB0303319D0 (de)
PT (1)	PT1597250E (de)
WO (1)	WO2004072062A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2246346B1 (de)	2005-07-11	2012-10-24	Novartis AG	Indolylmaleimid Derivate als Eiweiss Kinase Hemmer
EP2258357A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
EP2275096A3 (de)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenese durch modulation des Muscarinrezeptors
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
EP2314289A1 (de)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2021000A2 (de)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenese mittels angiotensin-modulation
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
JP2010513386A (ja)	2006-12-19	2010-04-30	ノバルティスアーゲー	キナーゼ阻害剤としてのインドリルマレイミド誘導体
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CN101671329B (zh) *	2009-06-17	2012-11-07	东华大学	3-氨基醇取代的吲哚马来酰亚胺化合物、其制备和应用
US9724331B2 (en)	2012-12-10	2017-08-08	Centogene Ag	Use of maleimide derivatives for preventing and treating leukemia
CN104693198B (zh) *	2014-12-13	2017-03-08	浙江工业大学	3‑(1,2,4‑三氮唑并[4,3‑a]吡啶‑3‑基)‑4‑(1H‑吲哚‑3‑基)马来酰亚胺类衍生物及其制备方法和应用
EP3292152A1 (de)	2015-05-07	2018-03-14	Agenus Inc.	Anti-ox40-antikörper und verfahren zur verwendung davon
WO2017096179A1 (en)	2015-12-02	2017-06-08	Agenus Inc.	Antibodies and methods of use thereof
CA3041340A1 (en)	2016-11-09	2018-05-17	Agenus Inc.	Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
WO2018132636A1 (en) *	2017-01-12	2018-07-19	The Research Foundation For The State University Of New York	[18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
CN110551103B (zh) *	2018-05-30	2022-08-23	北京大学深圳研究生院	一种jak3选择性抑制剂
WO2020163812A1 (en)	2019-02-08	2020-08-13	Frequency Therapeutics, Inc.	Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0629947B2 (ja)	1986-07-16	1994-04-20	正浩入江	光学記録材料
CZ280738B6 (cs)	1988-02-10	1996-04-17	F. Hoffmann - La Roche And Co., Aktiengesellschaft	Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
DE4005970A1 (de)	1990-02-26	1991-08-29	Boehringer Mannheim Gmbh	Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
GB9123396D0 (en)	1991-11-04	1991-12-18	Hoffmann La Roche	A process for the manufacture of substituted maleimides
AU3761393A (en)	1992-03-20	1993-10-21	Wellcome Foundation Limited, The	Indole derivatives with antiviral activity
JPH06161024A (ja)	1992-11-26	1994-06-07	Sanyo Electric Co Ltd	光学記録材料
US5405864A (en) *	1993-10-15	1995-04-11	Syntex (U.S.A.) Inc.	Chemotherapeutic maleimides
US5559228A (en) *	1995-03-30	1996-09-24	Eli Lilly And Company	Synthesis of bisindolylmaleimides
JPH0961647A (ja)	1995-08-25	1997-03-07	Nippon Telegr & Teleph Corp <Ntt>	光素子用有機材料
FR2772266B1 (fr)	1997-12-12	2000-02-04	Oreal	Utilisation d'agent de coloration photochrome dans une composition cosmetique, et composition cosmetique le comprenant
JP2002527419A (ja)	1998-10-08	2002-08-27	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類
GB9828640D0 (en)	1998-12-23	1999-02-17	Smithkline Beecham Plc	Novel method and compounds
DE10042603B4 (de)	1999-08-31	2010-04-29	Kyocera Corp.	Photochrome Verbindung und ihre Verwendung in optischen Funktionsvorrichtungen
AU1189201A (en)	1999-10-22	2001-05-08	Eli Lilly And Company	Therapeutic compositions including protein kinase c inhibitors
US6281356B1 (en)	1999-12-22	2001-08-28	Hoffmann-La Roche Inc.	Substituted pyrroles
DE60129222T2 (de)	2000-05-11	2008-03-06	Consejo Superior de Investigaciónes Científicas	Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3
CA2417277A1 (en)	2000-07-27	2002-02-07	F. Hoffmann-La Roche Ag	3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta.
CN1253449C (zh)	2000-11-07	2006-04-26	诺瓦提斯公司	作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物
JP2002285146A (ja)	2001-03-27	2002-10-03	Masahiro Irie	フォトクロミック組成物及び線量計
AU2002249103A1 (en)	2001-03-29	2002-10-15	Topo Target Aps	Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors
BE1014306A6 (fr)	2001-07-19	2003-08-05	Project 21C	Dispositif de stationnement d'un cycle avec antivol.
ATE368657T1 (de) *	2002-03-08	2007-08-15	Lilly Co Eli	Pyrrol-2,5-dion derivate und deren verwendung als gsk-3 inhibitoren
AR039209A1 (es) *	2002-04-03	2005-02-09	Novartis Ag	Derivados de indolilmaleimida

2003
- 2003-02-13 GB GBGB0303319.8A patent/GB0303319D0/en not_active Ceased
2004
- 2004-02-12 ES ES09004073T patent/ES2385071T3/es not_active Expired - Lifetime
- 2004-02-12 ES ES04710393T patent/ES2343115T3/es not_active Expired - Lifetime
- 2004-02-12 JP JP2005518422A patent/JP2006515004A/ja not_active Ceased
- 2004-02-12 AT AT09004073T patent/ATE551335T1/de active
- 2004-02-12 EP EP04710393A patent/EP1597250B8/de not_active Expired - Lifetime
- 2004-02-12 WO PCT/EP2004/001323 patent/WO2004072062A2/en not_active Ceased
- 2004-02-12 DE DE602004026415T patent/DE602004026415D1/de not_active Expired - Lifetime
- 2004-02-12 PT PT04710393T patent/PT1597250E/pt unknown
- 2004-02-12 EP EP09004073A patent/EP2075249B1/de not_active Expired - Lifetime
- 2004-02-12 CN CNB2004800029076A patent/CN100439359C/zh not_active Expired - Fee Related
- 2004-02-12 CA CA002513613A patent/CA2513613A1/en not_active Abandoned
- 2004-02-12 BR BRPI0407512-9A patent/BRPI0407512A/pt not_active IP Right Cessation
- 2004-02-12 US US10/542,175 patent/US7820672B2/en not_active Expired - Fee Related
- 2004-02-12 AT AT04710393T patent/ATE463491T1/de active
2009
- 2009-07-14 JP JP2009165725A patent/JP2009280592A/ja active Pending

Also Published As

Publication number	Publication date
WO2004072062A3 (en)	2004-11-04
ES2343115T3 (es)	2010-07-23
CA2513613A1 (en)	2004-08-26
GB0303319D0 (en)	2003-03-19
BRPI0407512A (pt)	2006-02-14
EP2075249B1 (de)	2012-03-28
CN100439359C (zh)	2008-12-03
CN1742005A (zh)	2006-03-01
US7820672B2 (en)	2010-10-26
PT1597250E (pt)	2010-06-25
EP1597250B1 (de)	2010-04-07
EP1597250A2 (de)	2005-11-23
JP2009280592A (ja)	2009-12-03
EP2075249A2 (de)	2009-07-01
US20060058356A1 (en)	2006-03-16
DE602004026415D1 (de)	2010-05-20
JP2006515004A (ja)	2006-05-18
ATE551335T1 (de)	2012-04-15
ES2385071T3 (es)	2012-07-17
WO2004072062A2 (en)	2004-08-26
EP2075249A3 (de)	2009-09-02
EP1597250B8 (de)	2010-05-19

Legal Events

Date

Code

Title

Description

2010-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1597250

Country of ref document: EP

Publication	Publication Date	Title
DE602004026415D1 (de)	2010-05-20	Indolylmaleimid derivate
ECSP12006206A (es)	2012-03-30	Inhibidores de quinasa p38 basados en heterociclos de 5 miembros.
MXPA05009595A (es)	2005-11-04	Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
EP1954274A4 (de)	2009-01-07	Substituierte chinolone und verwendungsverfahren
CY1116754T1 (el)	2017-03-15	Παραγωγα νιτροκατεχολης ως αναστολεις της comt
CY1110965T1 (el)	2015-06-11	Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
PL1682138T6 (pl)	2013-03-29	Heterocykliczne inhibitory MEK
NO20062561L (no)	2006-09-08	Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20053211D0 (no)	2005-06-30	Forbindelser for behandling av metabolske forstyrrelser.
DE60121345D1 (de)	2006-08-17	Alkylierte imidazopyridinderivate
DK1313740T3 (da)	2006-04-03	Prodrugs af imidazopyridinderivater
BRPI0509660A (pt)	2007-10-09	compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
PL1900362T3 (pl)	2011-06-30	Pochodne alfa-aminoamidu użyteczne w leczeniu zaburzeń uzależnieniowych
ATE449776T1 (de)	2009-12-15	Pyrroloä2,3-cüpyridinderivate
PT1606233E (pt)	2006-09-29	Derivados de esteres lipidicos de nucleotidos
UA86873C2 (en)	2009-05-25	SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
ATE473737T1 (de)	2010-07-15	Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung
DK1951718T3 (da)	2012-05-14	4-Oxadiazolyl-piperidinforbindelser og anvendelse deraf